Egetis Therapeutics

Board/Management Information • Nov 5, 2021

PRESSMEDDELANDE

Egetis Therapeutics AB Stockholm, Sweden, November 5, 2021

Nomination Committee appointed for the 2022 Annual General Meeting in Egetis Therapeutics

The Chairman of Egetis Therapeutics AB (publ) (ticker: EGTX) has established a Nomination Committee according to the process approved by the 2021 Annual General Meeting. The 2022 AGM is planned to be held on May 10, 2022 at 3.00 pm (CET). The Nomination Committee is composed of members appointed by the three largest shareholders in terms of voting rights, that have accepted the invitation to join the committee.

The following members have been appointed by the subsequent shareholders: Cidro Förvaltning AB: Peter Lindell Avla Holding AB: Kennet Rooth Fjärde AP-fonden: Jannis Kitsakis

The Nomination Committee has elected Kennet Rooth as chairman. Thomas Lönngren, Chairman of the Board of Directors, will co-opt to the Nomination Committee.

In total, the Nomination Committee represents approx. 29% of the total number of shares and votes in the company. All representatives are independent in relation to the company and its executive management. Peter Lindell and Jannis Kitsakis are also independent in relation to Cetoros AB, which is the largest shareholder in the company in terms of votes but has declined participation in the committee.

The Committee's assignment is to present proposals regarding Chairman and other members of the Board, as well as remuneration to the Board´s members, to the Annual General Meeting (AGM). The Nomination Committee shall also submit proposals for appointment and remuneration of auditors. Further, the Committee shall submit proposals regarding the process to appoint the Nomination Committee for the AGM in 2023.

Shareholders who wish to submit proposals to the Nomination Committee can do so by email: lonngren@me.com

For further information, please contact:

Yilmaz Mahshid Ph.D., CFO Email: yilmaz.mahshid@egetis.com.

The information was submitted for publication, through the agency of the contact person set out above, at 2021-11-05, 08:00 CET.

About Egetis Therapeutics

Egetis Therapeutics is an innovative, unique, and integrated pharmaceutical drug development company, focusing on projects in late-stage development for treatment of serious diseases with significant unmet medical needs in the orphan drug segment. The drug candidate Emcitate is developed as the first potential treatment for patients with MCT8 deficiency, a rare disease with high unmet medical need and no available treatment. A Phase IIb clinical trial has been completed with significant and clinically relevant effects. A Phase IIb/III early intervention study has been initiated with the first patient dosed in Dec 2020. Emcitate holds Orphan Drug Designation (ODD) in the US and EU and has been granted Rare Pediatric Disease Designation and Fast Track Designation by the US FDA. The drug candidate Aladote is a first in class drug candidate developed to reduce the

risk of acute liver injury associated with paracetamol poisoning. A proof of principle study has been successfully completed and the design of the upcoming pivotal Phase IIb/III study for Aladote has been finalized after completed interactions with FDA, EMA and MHRA. Aladote has been granted Orphan Drug Designation in the US and an application for ODD was submitted in Europe in Q1 2021. There is an ongoing dialogue with EMA on the appropriate indication for an ODD in the EU.

Egetis Therapeutics (STO: EGTX) is listed on the Nasdaq Stockholm main market since October 31, 2019. For more information, see www.egetis.com